Skip to Content

Xipere Approval Status

FDA Approved: No
Brand name: Xipere
Generic name: triamcinolone acetonide
Dosage form: Injection
Company: Clearside Biomedical, Inc.
Treatment for: Macular Edema, Uveitis

Xipere (triamcinolone acetonide) is a proprietary corticosteroid suspension for suprachoroidal injection in development for the treatment of macular edema associated with uveitis.

Development Status and FDA Approval Process for Xipere

DateArticle
Aug 22, 2019Clearside Biomedical Provides New Drug Application Update for Xipere (triamcinolone acetonide suprachoroidal injectable suspension)
Dec 19, 2018Clearside Biomedical Submits New Drug Application for Xipere for the Treatment of Macular Edema Associated with Uveitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide